Genome-Scale Mutational Signatures Of Aflatoxin In Cells, Mice And Human Tumors
M. N. Huang, W. Yu, W. W. Teoh, M. Ardin, A. Jusakul, A. Ng, A. Boot, B. Abedi-Ardekani, S. Villar, S. S. Myint, R. Othman, S. L. Poon, A. Heguy, M. Olivier, M. Hollstein, P. Tan, B. T. Teh, K. Sabapathy, J. Zavadil, S. Rozen
Abstract
Aflatoxin B1 (AFB1) is a mutagen and IARC Group 1 carcinogen that causes hepatocellular carcinoma (HCC). Here we present the first whole genome data on the mutational signatures of AFB1 exposure from a total of > 40,000 mutations in four experimental systems: two different human cell lines, and in liver tumors in wild-type mice and in mice that carried a hepatitis B surface antigen transgene - this to model the multiplicative effects of aflatoxin exposure and hepatitis B in causing HCC. AFB1 mutational signatures from all four experimental systems were remarkably similar. We integrated the experimental mutational signatures with data from newly-sequenced HCCs from Qidong County, China, a region of well-studied aflatoxin exposure. This indicated that COSMIC mutational signature 24, previously hypothesized to stem from aflatoxin exposure, indeed likely represents AFB1 exposure, possibly combined with other exposures. Among published somatic mutation data, we found evidence of AFB1 exposure in 0.7% of HCCs treated in North America, 1% of HCCs from Japan, but 16% of HCCs from Hong Kong. Thus, aflatoxin exposure apparently remains a substantial public health issue in some areas. This aspect of our study exemplifies the promise of future widespread resequencing of tumor genomes in providing new insights into the contribution of mutagenic exposures to cancer incidence.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genome-wide association study of TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and hepatitis B virus infection in Guangxi
Chuangye Han, Tingdong Yu, … Tao Peng·Journal of Gastrointestinal OncologyPeer-reviewed·Dec 1, 2020
- Evaluating the therapeutic efficacy of the US FDA-designated Orphan drug, uttroside B in impeding hepatocarcinogenesis via induction of immunogenic apoptosis, using a murine model of Aflatoxin B1-induced liver carcinogenesis
Mundanattu Swetha, Chenicheri Kizhakkeveettil Keerthana, … Ruby John Anto·bioRxiv·Sep 8, 2025
- Mutational landscape of a chemically-induced mouse model of liver cancer
F. Connor, T. F. Rayner, … D. T. Odom·bioRxiv·Jan 4, 2018
- Experimental analysis of exome-scale mutational signature of glycidamide, the reactive metabolite of acrylamide
Maria Zhivagui, Alvin Wei Tian Ng, … Jiří Zavadil·Genome ResearchPeer-reviewed·Apr 1, 2019
- In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
A. Boot, M. N. Huang, … S. G. Rozen·bioRxiv·Dec 17, 2017
- Defining mutational signatures of lung cancer-associated carcinogens through in vitro exposure of human airway epithelial cells
Natasha Q. Gurevich, Darren Jianjhih Chiu, … Joshua David Campbell·bioRxiv·Mar 9, 2026